Treating Lung Disease - Bronchodilator Medicine 2024-25 Edition

When comparing plans, small differences between scores are expected. The larger differences are important.

Treating Lung Disease - Bronchodilator Medicine

  • (Worse)
    0%
  • (Better)
    100%
Kaiser Permanente - Northern California - HMO 96%
Horizontal bar, 96 units
Horizontal bar, 96 units
Aetna - PPO 95%
Horizontal bar, 95 units
Horizontal bar, 95 units
Aetna Health of California, Inc. - HMO 95%
Horizontal bar, 95 units
Horizontal bar, 95 units
Kaiser Permanente - Southern California - HMO 94%
Horizontal bar, 94 units
Horizontal bar, 94 units
Blue Shield of California - HMO 90%
Horizontal bar, 90 units
Health Net of California, Inc. - HMO 90%
Horizontal bar, 90 units
CIGNA - PPO 80%
Horizontal bar, 80 units
Blue Shield of California/Blue Shield Life - PPO 79%
Horizontal bar, 79 units
Anthem Blue Cross - HMO 78%
Horizontal bar, 78 units
Anthem Blue Cross - PPO 78%
Horizontal bar, 78 units
UnitedHealthcare of California - HMO 78%
Horizontal bar, 78 units
UnitedHealthcare Insurance Co., Inc. - PPO 75%
Horizontal bar, 75 units
CIGNA - HMO Too few patients in sample to report
Health Net of California, Inc. - PPO Too few patients in sample to report
Sharp Health Plan - HMO Too few patients in sample to report
Western Health Advantage - HMO Too few patients in sample to report
Score for top health plans nationwide  91%       
Score that ranks a health plan in the top 10% of all commercial health plans in the US.

Data Disclaimer  
The data source for data for the Report Cards is Quality Compass® 2024 and is used with the permission of the National Committee for Quality Assurance (NCQA). Quality Compass® 2024 includes Healthcare Effectiveness Data and Information Set (HEDIS®) and Consumer Assessment of Healthcare Providers and Systems (CAHPS®) data. Any data display, analysis, interpretation, or conclusion based on these data is solely that of the authors. NCQA specifically disclaims responsibility for any such display, analysis, interpretation, or conclusion. Quality Compass and HEDIS are registered trademarks of NCQA. CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).

Users of the data shall not have the right to alter, enhance, or otherwise modify the data. Anyone who wants to use or reproduce the data without modification for a noncommercial purpose may do so without obtaining any approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA. Use by healthcare providers in connection with their own practices is not commercial use. A "commercial use" refers to any sale, license, or distribution of the data for commercial gain, or incorporation of the data into any product or service that is sold, licensed, or distributed for commercial gain, even if there is no actual charge for inclusion of the data. ©2004-2024 National Committee for Quality Assurance, all rights reserved.

311.110/311.210